1.49
Beyondspring Inc stock is traded at $1.49, with a volume of 37,531.
It is down -4.67% in the last 24 hours and down -15.88% over the past month.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.
See More
Previous Close:
$1.50
Open:
$1.5
24h Volume:
37,531
Relative Volume:
2.84
Market Cap:
$60.97M
Revenue:
$1.88M
Net Income/Loss:
$-15.57M
P/E Ratio:
-3.725
EPS:
-0.4
Net Cash Flow:
$-50.09M
1W Performance:
-0.69%
1M Performance:
-15.88%
6M Performance:
-39.66%
1Y Performance:
-45.00%
Beyondspring Inc Stock (BYSI) Company Profile
Name
Beyondspring Inc
Sector
Industry
Phone
646-528-4184
Address
100 CAMPUS DRIVE, WEST SIDE, 4TH FLOOR, FLORHAM PARK, NY
Compare BYSI with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
BYSI
Beyondspring Inc
|
1.49 | 60.97M | 1.88M | -15.57M | -50.09M | -0.40 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
479.50 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
582.50 | 65.79B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
558.18 | 35.18B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
240.09 | 32.67B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
241.06 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Beyondspring Inc Stock (BYSI) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-02-21 | Downgrade | BofA Securities | Buy → Underperform |
Dec-02-21 | Downgrade | Jefferies | Buy → Hold |
Dec-01-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
Dec-01-21 | Downgrade | William Blair | Outperform → Mkt Perform |
Sep-09-21 | Initiated | Robert W. Baird | Outperform |
Aug-04-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
Apr-05-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
Jan-11-21 | Initiated | BofA Securities | Buy |
Dec-29-20 | Initiated | Evercore ISI | Outperform |
Feb-07-20 | Initiated | Jefferies | Buy |
Jan-10-20 | Initiated | Nomura | Buy |
Dec-03-19 | Initiated | William Blair | Outperform |
Jul-10-19 | Reiterated | H.C. Wainwright | Buy |
Apr-30-19 | Downgrade | Maxim Group | Buy → Hold |
Oct-25-18 | Reiterated | Maxim Group | Buy |
View All
Beyondspring Inc Stock (BYSI) Latest News
BeyondSpring (NASDAQ:BYSI) Trading Down 3.8%Here's Why - MarketBeat
BeyondSpring’s 2024 Progress and Strategic Milestones - TipRanks
BeyondSpring stock hits 52-week low at $1.4 amid sharp decline By Investing.com - Investing.com South Africa
BeyondSpring stock hits 52-week low at $1.4 amid sharp decline - Investing.com
BeyondSpring Inc. (BYSI) reports earnings - Quartz
BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones - The Manila Times
BeyondSpring Files 2024 Annual Report on Form 10-K - GlobeNewswire
Just Released: BeyondSpring's Complete 2024 Financial Performance and Cancer Pipeline Updates - Stock Titan
Global Febrile Neutropenia Market Forecast 2025-2034: Analyzing Growth Drivers, Market Share, Segments, And - EIN News
In-Depth Analysis Of The Global Febrile Neutropenia Market Advancements Highlighted by Key Drivers, Trends,... - WhaTech
BeyondSpring's PlinabulinA Pipeline In Itself? - RTTNews
Molecular Glues Market to Register Stunning Growth During the Forecast Period (2025-2034) | DelveInsight - The Malaysian Reserve
BeyondSpring, Inc. to Host Earnings Call - ACCESS Newswire
Pliant Therapeutics stock tumbles amid IPF trial cancellation - Clinical Trials Arena
BeyondSpring finalizes significant asset sale By Investing.com - Investing.com South Africa
BeyondSpring finalizes significant asset sale - Investing.com India
BeyondSpring (NASDAQ:BYSI) Stock Price Up 0.6%Time to Buy? - MarketBeat
Cancer Vaccines Market on Track for Major Expansion in - One News Page
Cancer Index takes hit in 2024 amid regulatory setbacks, failures - BioWorld Online
Deal Watch: Novo Nordisk, IMMvention To Partner On Sickle Cell Disease - Citeline News & Insights
SEED Therapeutics Secures FDA Rare Pediatric and Orphan Drug Designations for ST-01156 - MSN
BeyondSpring Inc. Enters into Preferred Share Purchase Agreement with SEED Therapeutics Inc. - Defense World
BeyondSpring sells SEED Therapeutics shares for $35.4M - MSN
SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors - The Manila Times
BeyondSpring sells SEED Therapeutics shares for $35.4M By Investing.com - Investing.com UK
BeyondSpring Announces $35.4 Million Sale of a Portion of - GlobeNewswire
SEED Receives FDA Rare Pediatric Disease and Orphan Drug - GlobeNewswire
BeyondSpring Cashes In $35M Stake as Cancer Drug Shows 89% Disease Control Rate - StockTitan
BeyondSpring (NASDAQ:BYSI) Shares Down 1.4%Here's Why - MarketBeat
Non-Small Cell Lung Cancer Clinical Trial Pipeline Boom as Over 100 Companies Leading the Charge in Research and Development | DelveInsight - The Malaysian Reserve
BeyondSpring Inc. Announces Change in Domestic Filing Status and Disclosure Channels to Disseminate Information - Defense World
BeyondSpring (BYSI) Stock Drops Amidst Biotech Sector Volatility - GuruFocus.com
Germ Cell Tumors Market to Register Significant Growth at a CAGR of 5.5% by 2034 | DelveInsight - The Malaysian Reserve
CTLA-4 Inhibitors Market to Advance at Moderate CAGR During the Study Period (2020-2034) | DelveInsight - The Malaysian Reserve
Retail investors reap multibagger gains by betting on these 29 - Oficjalny Portal Gminy Brzesko
BeyondSpring (NASDAQ:BYSI) Shares Up 4.5%Here's Why - MarketBeat
BeyondSpring (NASDAQ:BYSI) Trading 4.5% Higher – Here’s Why - Defense World
Non-small Cell Lung Cancer Treatment Market 2032: Clinical Trials, Medication, Prevalence, Incidence, Therapies, EMA, PDMA, FDA Approvals, and Companies by DelveInsight - The Globe and Mail
Non-small Cell Lung Cancer Treatment Market 2032: Clinical - openPR
Beyondspring Inc Stock (BYSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):